Completed

OSI-7904L for Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Over 18 Years
+7 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: October 2003
See protocol details

Summary

Principal SponsorOSI Pharmaceuticals
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: October 1, 2003

Actual date on which the first participant was enrolled.

This is a study looking into the safety and effectiveness of a drug called OSI-7904L for treating advanced stomach or gastroesophageal junction (GEJ) adenocarcinoma, a type of cancer. The study focuses on individuals with these specific types of cancer. The goal is to find new ways to help these patients, as current treatments may not be working well enough or have side effects that are hard to handle. During this study, participants will receive OSI-7904L as a single agent treatment. If they don't show improvement after two cycles, they may switch to a different, commonly used combination of drugs. The study will monitor the participants' health to see how well the treatment works and if there are any side effects. It's important to note that participants might experience benefits or risks associated with this treatment, as with any clinical trial.

Official TitleA Phase II Study of Single Agent OSI-7904L In Patients With Locally Advanced or Metastatic Adenocarcinoma Of the Stomach or Gastroesophageal Junction
NCT00073502
Principal SponsorOSI Pharmaceuticals
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

43 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

5 inclusion criteria required to participate
Documented locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction
No prior chemotherapy for locally advanced or metastatic disease
Adequate baseline bone marrow, hepatic and renal function
Age >= 18 years
Show More Criteria
2 exclusion criteria prevent from participating
Active or uncontrolled infections or other serious illnesses or other medical conditions (eg, hepatitis, HIV, chronic alcohol abuse)
Symptomatic brain metastases which are not stable

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 11 locations

Suspended

University of Pennsylvania Cancer Center

Philadelphia, United StatesOpen University of Pennsylvania Cancer Center in Google Maps
Suspended

MD Anderson Cancer Center

Houston, United States
Suspended

University of Utah, Huntsman Cancer Institute

Salt Lake City, United States
Suspended

Dept Internal Medicine Gastrointestinal Oncology Unit

B-3000 Leuven, Belgium
Completed11 Study Centers